Return to search results.
Complete title: A Multicenter, Open-Label, Phase II Study of the Brutons Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma
|Research Study Number||20132187|
|Principal Investigator||Stephen Smith|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Hematologic Malignancies; Lymphoma; Lymphoproliferative Disease
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.